Key result
A FRET-based whole-cell lysate RNase H2 activity assay demonstrated methodological variability of 8.6% to 16% and detected reduced activity in three patients with autoimmune diseases.
Why the study?
RNase H2 loss contributes to autoinflammatory, autoimmune, and other diseases, but no method for quantifying RNase H2 activity had been validated for the clinical setting.
A newly validated FRET-based assay enables standardized quantification of RNase H2 activity in clinical samples, showing potential for screening in autoimmune diseases.
Answers are grounded in this paper and cite their sources.
May support RNase H2 screening in autoimmune diseases; leaves open clinical adoption pending larger validation.
As the key enzyme mediating ribonucleotide excision repair, RNase H2 is essential for the removal of single ribonucleotides from DNA in order to prevent genome damage. Loss of RNase H2 activity directly contributes to the pathogenesis of autoinflammatory and autoimmune diseases and might further play a role in ageing and neurodegeneration. Moreover, RNase H2 activity is a potential diagnostic and prognostic marker in several types of cancer. Until today, no method for quantification of RNase H2 activity has been validated for the clinical setting. Herein, validation and benchmarks of a FRET-based whole-cell lysate RNase H2 activity assay are presented, including standard conditions and procedures to calculate standardized RNase H2 activity. Spanning a wide working range, the assay is applicable to various human cell or tissue samples with overall methodological assay variability from 8.6% to 16%. Using our assay, we found RNase H2 activity was reduced in lymphocytes of two patients with systemic lupus erythematosus and one with systemic sclerosis carrying heterozygous mutations in one of the RNASEH2 genes. Implementation of larger control groups will help to assess the diagnostic and prognostic value of clinical screening for RNase H2 activity in the future.
No takes yet. Share an insight, caveat, or question.
Schulz et al. (2023) studied Systemic lupus erythematosus and systemic sclerosis (n=3). FRET-based whole-cell lysate RNase H2 activity assay was evaluated on Methodological assay variability. A FRET-based whole-cell lysate RNase H2 activity assay demonstrated methodological variability of 8.6% to 16% and detected reduced activity in three patients with autoimmune diseases.
Synapse has enriched 10 related papers. Consider them for comparative context: